Evidence map›Paper›PMID 28100026›Full record

ArticleCancer science2017

miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver.

Xiao-Bo Zheng, Xiao-Bo Chen, Liang-Liang Xu, Ming Zhang, Lei Feng, Peng-Sheng Yi, Jian-Wei Tang, Ming-Qing Xu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Diagnostic and prognostic significance of serum miR-203 in patients with acute myeloid leukemia.International journal of clinical and experimental pathology · 2019
    Article
  15. [miR-203 inhibits lung cancer cell metastasis by targeting fatty acid binding protein 4].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018
    Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiao-Bo ZhengDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0003-1361-6851
Xiao-Bo ChenDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Liang-Liang XuDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Ming ZhangDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Lei FengDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Peng-Sheng YiDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Jian-Wei TangDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Ming-Qing XuDepartment of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Sichuan University · CNKunming University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver resection is still the most commonly used therapeutic treatment for hepatocellular carcinoma (HCC), and liver regeneration promotes HCC growth in the regenerating liver. The high recurrence/metastasis of HCC is the main cause of death for HCC patients after liver resection. However, how the augmented growth and metastasis of residual HCC induced by the promoted liver regeneration following liver resection can be abolished remains unclear. In this study, a rat model with liver cirrhosis and diffused HCC was established by administration of diethylnitrosamine. Recombinant miR-203 adenovirus was administered to induce hepatic miR-203 overexpression and 30% partial hepatectomy (PH) followed. The effect of miR-203 on the proliferation, invasion and metastasis of the residual HCC in the remnant cirrhotic liver with promoted regeneration was investigated. We found that the basic spontaneous regeneration of the non-tumorous liver by 30% PH promoted proliferation, invasion and lung metastasis of the hepatic residual HCC. miR-203 overexpression further promoted the regeneration of the non-tumorous liver by upregulating Ki67 expression and enhancing IL-6/SOCS3/STAT3 pro-proliferative signals. Importantly, miR-203 overexpression markedly inhibited the proliferation, invasion and metastasis of hepatic residual HCC through suppressing expression of Ki67, CAPNS1 and lung metastasis. Moreover, it was found that miR-203 overexpression reversed the epithelial-mesenchymal transition induced by hepatectomy through targeting IL-1β, Snail1 and Twist1. In conclusion, our results suggested that miR-203 overexpression inhibited the augmented proliferation and lung metastasis of the residual HCC induced by the promoted liver regeneration following PH partly by regulating epithelial-mesenchymal transition.

Indexed as

AnimalsCalpainCarcinoma, HepatocellularCell MovementCell ProliferationDiethylnitrosamineEpithelial-Mesenchymal TransitionHepatectomyInterleukin-1betaInterleukin-6Ki-67 AntigenLiverLiver NeoplasmsMaleMicroRNAsNeoplasm InvasivenessCalpainCapns1 protein, ratDiethylnitrosamineIL1B protein, ratInterleukin-1betaInterleukin-6Ki-67 AntigenMicroRNAsMIRN203 microRNA, ratsnai1 protein, ratSnail Family Transcription FactorsSocs3 protein, ratStat3 protein, ratSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 ProteinTwist1 protein, ratTwist-Related Protein 1Hepatectomyhepatocellular carcinomaliver regenerationmiR-203 overexpressionproliferation and metastasis

Identifiers

PMID28100026
PMCPMC5378262
OpenAlexW2571556565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.